Copeland Capital Management’s LeMaitre Vascular LMAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $76.3M | Buy |
924,081
+84,618
| +10% | +$7.49M | 1.76% | 4 |
|
|
2026
Q2 | $80.6M | Sell |
839,463
-31,229
| -4% | -$3.2M | 1.65% | 11 |
|
|
2026
Q1 | $95.1M | Sell |
870,692
-18,285
| -2% | -$1.74M | 2.11% | 3 |
|
|
2025
Q4 | $72.1M | Sell |
888,977
-51,351
| -5% | -$4.42M | 1.61% | 11 |
|
|
2025
Q3 | $82.3M | Sell |
940,328
-49,709
| -5% | -$4.44M | 1.71% | 5 |
|
|
2025
Q2 | $82.2M | Sell |
990,037
-88,686
| -8% | -$7.41M | 1.69% | 6 |
|
|
2025
Q1 | $90.5M | Sell |
1,078,723
-93,292
| -8% | -$8.68M | 1.81% | 7 |
|
|
2024
Q4 | $108M | Buy |
1,172,015
+8,623
| +0.7% | +$829K | 2.01% | 4 |
|
|
2024
Q3 | $108M | Buy |
1,163,392
+11,318
| +1% | +$981K | 1.88% | 4 |
|
|
2024
Q2 | $94.8M | Sell |
1,152,074
-138,819
| -11% | -$10.2M | 1.77% | 8 |
|
|
2024
Q1 | $85.7M | Buy |
1,290,893
+30,932
| +2% | +$1.91M | 1.56% | 13 |
|
|
2023
Q4 | $71.5M | Buy |
1,259,961
+28,720
| +2% | +$1.5M | 1.43% | 20 |
|
|
2023
Q3 | $67.1M | Buy |
1,231,241
+5,515
| +0.4% | +$327K | 1.44% | 22 |
|
|
2023
Q2 | $82.5M | Sell |
1,225,726
-139,016
| -10% | -$8.48M | 1.7% | 7 |
|
|
2023
Q1 | $70.2M | Buy |
1,364,742
+87,264
| +7% | +$4.24M | 1.65% | 12 |
|
|
2022
Q4 | $58.8M | Buy |
1,277,478
+53,896
| +4% | +$2.52M | 1.55% | 16 |
|
|
2022
Q3 | $62M | Buy |
1,223,582
+11,276
| +0.9% | +$563K | 2.05% | 4 |
|
|
2022
Q2 | $55.2M | Sell |
1,212,306
-2,699
| -0.2% | -$121K | 1.75% | 8 |
|
|
2022
Q1 | $56.5M | Buy |
1,215,005
+9,806
| +0.8% | +$439K | 1.56% | 13 |
|
|
2021
Q4 | $60.5M | Buy |
1,205,199
+80,112
| +7% | +$4.14M | 1.57% | 13 |
|
|
2021
Q3 | $59.7M | Buy |
1,125,087
+62,054
| +6% | +$3.5M | 1.7% | 5 |
|
|
2021
Q2 | $64.9M | Buy |
1,063,033
+171,708
| +19% | +$9.12M | 1.95% | 5 |
|
|
2021
Q1 | $43.5M | Sell |
891,325
-60,170
| -6% | -$2.82M | 1.35% | 36 |
|
|
2020
Q4 | $38.5M | Buy |
951,495
+63,577
| +7% | +$2.27M | 1.52% | 25 |
|
|
2020
Q3 | $28.9M | Buy |
887,918
+221,953
| +33% | +$6.66M | 1.28% | 38 |
|
|
2020
Q2 | $17.6M | Buy |
665,965
+24,917
| +4% | +$651K | 0.91% | 48 |
|
|
2020
Q1 | $16M | Buy |
641,048
+79,975
| +14% | +$2.47M | 0.97% | 43 |
|
|
2019
Q4 | $20.2M | Buy |
561,073
+20,588
| +4% | +$710K | 0.88% | 47 |
|
|
2019
Q3 | $18.5M | Buy |
540,485
+152,753
| +39% | +$4.88M | 0.95% | 42 |
|
|
2019
Q2 | $10.8M | Buy |
387,732
+209,913
| +118% | +$5.83M | 0.6% | 59 |
|
|
2019
Q1 | $5.51M | Buy |
177,819
+177,086
| +24,159% | +$4.73M | 0.35% | 77 |
|
|
2018
Q4 | $17K | Buy |
+733
| New | +$20K | ﹤0.01% | 163 |
|
Other funds holding LMAT
Copeland Capital Management's LMAT Position: Q3 2026 in Review
Copeland Capital Management increased its LeMaitre Vascular (LMAT) stake by 10% in Q3 2026, buying an estimated $7.49M and bringing the position to 924,081 shares worth $76.3M. The position accounts for 1.76% of the portfolio, ranked #4.
Copeland Capital Management first reported a position in LMAT in Q4 2018 and has held it in 32 quarters since. The position peaked at $108M in Q3 2024. 217 funds tracked by Wall St. Rank hold LMAT as of Q3 2026.
- Copeland Capital Management held 924,081 shares of LeMaitre Vascular worth $76.3M as of Q3 2026.
- Copeland Capital Management bought 84,618 LeMaitre Vascular shares in Q3 2026, an estimated $7.49M.
- LeMaitre Vascular made up 1.76% of Copeland Capital Management's portfolio in Q3 2026, its #4 holding.
- Copeland Capital Management first reported a position in LeMaitre Vascular in Q4 2018 and has held it in 32 quarters since.
- Copeland Capital Management's LeMaitre Vascular position peaked at $108M in Q3 2024.
- 217 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q3 2026.
Based on Copeland Capital Management's 13F filing for Q3 2026, filed 13 Oct 2026.